References(47)
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607–20.
Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol. 2009;6:699–708.
Fukuchi J, Kokontis JM, Hiipakka RA, Chuu CP, Liao S. Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells. Cancer Res. 2004;64:7686–9.
Hong C, Tontonoz P. Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr Opin Genet Dev. 2008;18:461–7.
Russo V. Metabolism, LXR/LXR ligands, and tumor immune escape. J Leukoc Biol. 2011;90:673–9.
Tontonoz P, Mangelsdorf DJ. Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol. 2003;17:985–93.
Xiao X, Wang P, Chou KC. Recent progresses in identifying nuclear receptors and their families. Curr Top Med Chem. 2013;13:1192–200.
Collins JL, Fivush AM, Watson MA, Galardi CM, Lewis MC, Moore LB, et al. Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J Med Chem. 2002;45:1963–6.
Candelaria NR, Addanki S, Zheng J, Nguyen‐Vu T, Karaboga H, Dey P, et al. Antiproliferative effects and mechanisms of liver X receptor ligands in pancreatic ductal adenocarcinoma cells. PLOS One. 2014;9:e106289.
Joseph SB, McKilligin E, Pei L, Watson MA, Collins AR, Laffitte BA, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A. 2002;99:7604–9.
Populo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. Int J Mol Sci. 2012;13:1886–918.
Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18:1926–45.
LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Update. 2008;11:32–50.
Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol. 2007;9:316–23.
Xu J, Ji J, Yan XH. Cross‐talk between AMPK and mTOR in regulating energy balance. Crit Rev Food Sci Nutr. 2012;52:373–81.
Ma L, Chen Z, Erdjument‐Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell. 2005;121:179–93.
Ma L, Teruya‐Feldstein J, Bonner P, Bernardi R, Franz DN, Witte D, et al. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal‐regulated kinase‐mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res. 2007;67:7106–12.
Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004;18:2893–904.
Schneider A, Younis RH, Gutkind JS. Hypoxia‐induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma. Neoplasia. 2008;10:1295–302.
Whitney ML, Jefferson LS, Kimball SR. ATF4 is necessary and sufficient for ER stress‐induced upregulation of REDD1 expression. Biochem Biophys Res Commun. 2009;379:451–5.
Jin HO, Seo SK, Kim YS, Woo SH, Lee KH, Yi JY, et al. TXNIP potentiates REDD1‐induced mTOR suppression through stabilization of REDD1. Oncogene. 2011;30:3792–801.
Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989;24:148–54.
Wang Z, Malone MH, He H, McColl KS, Distelhorst CW. Microarray analysis uncovers the induction of the proapoptotic BH3‐only protein Bim in multiple models of glucocorticoid‐induced apoptosis. J Biol Chem. 2003;278:23861–7.
Wang Z, Malone MH, Thomenius MJ, Zhong F, Xu F, Distelhorst CW. Dexamethasone‐induced gene 2 (dig2) is a novel pro‐survival stress gene induced rapidly by diverse apoptotic signals. J Biol Chem. 2003;278:27053–8.
Zhang A, Sieglaff DH, York JP, Suh JH, Ayers SD, Winnier GE, et al. Thyroid hormone receptor regulates most genes independently of fibroblast growth factor 21 in liver. J Endocrinol. 2015;224:289–301.
Deer EL, Gonzalez‐Hernandez J, Coursen JD, Shea JE, Ngatia J, Scaife CL, et al. Phenotype and genotype of pancreatic cancer cell lines. Pancreas. 2010;39:425–35.
Jin HO, Seo SK, Woo SH, Kim ES, Lee HC, Yoo DH, et al. SP600125 negatively regulates the mammalian target of rapamycin via ATF4‐induced REDD1 expression. FEBS Lett. 2009;583:123–7.
Kimball SR, Jefferson LS. Induction of REDD1 gene expression in the liver in response to endoplasmic reticulum stress is mediated through a PERK, eIF2alpha phosphorylation, ATF4‐dependent cascade. Biochem Biophys Res Commun. 2012;427:485–9.
Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME, et al. Dysregulation of sterol response element‐binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res. 2004;64:2212–21.
Sporer A, Brill DR, Schaffner CP. Epoxycholesterols in secretions and tissues of normal, benign, and cancerous human prostate glands. Urology. 1982;20:244–50.
Lin CY, Gustafsson JA. Targeting liver X receptors in cancer therapeutics. Nat Rev Cancer. 2015;15:216–24.
Rough JJ, Monroy MA, Yerrum S, Daly JM. Anti‐proliferative effect of LXR agonist T0901317 in ovarian carcinoma cells. J Ovarian Res. 2010;3:13.
Vedin LL, Lewandowski SA, Parini P, Gustafsson JA, Steffensen KR. The oxysterol receptor LXR inhibits proliferation of human breast cancer cells. Carcinogenesis. 2009;30:575–9.
Geyeregger R, Shehata M, Zeyda M, Kiefer FW, Stuhlmeier KM, Porpaczy E, et al. Liver X receptors interfere with cytokine‐induced proliferation and cell survival in normal and leukemic lymphocytes. J Leukoc Biol. 2009;86:1039–48.
Fukuchi J, Hiipakka RA, Kokontis JM, Hsu S, Ko AL, Fitzgerald ML, et al. Androgenic suppression of ATP‐binding cassette transporter A1 expression in LNCaP human prostate cancer cells. Cancer Res. 2004;64:7682–5.
Kim KH, Lee GY, Kim JI, Ham M, Won Lee J, Kim JB. Inhibitory effect of LXR activation on cell proliferation and cell cycle progression through lipogenic activity. J Lipid Res. 2010;51:3425–33.
Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, et al. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP‐1/LDLR‐dependent pathway. Cancer Discov. 2011;1:442–56.
Chuu CP, Chen RY, Hiipakka RA, Kokontis JM, Warner KV, Xiang J, et al. The liver X receptor agonist T0901317 acts as androgen receptor antagonist in human prostate cancer cells. Biochem Biophys Res Commun. 2007;357:341–6.
Lee JH, Gong H, Khadem S, Lu Y, Gao X, Li S, et al. Androgen deprivation by activating the liver X receptor. Endocrinology. 2008;149:3778–88.
Nguyen‐Vu T, Vedin LL, Liu K, Jonsson P, Lin JZ, Candelaria NR, et al. Liver X receptor ligands disrupt breast cancer cell proliferation through an E2F‐mediated mechanism. Breast Cancer Res. 2013;15:R51.
Villablanca EJ, Raccosta L, Zhou D, Fontana R, Maggioni D, Negro A, et al. Tumor‐mediated liver X receptor‐alpha activation inhibits CC chemokine receptor‐7 expression on dendritic cells and dampens antitumor responses. Nat Med. 2010;16:98–105.
Wang Q, Ma X, Chen Y, Zhang L, Jiang M, Li X, et al. Identification of interferon‐gamma as a new molecular target of liver X receptor. Biochem J. 2014;459:345–54.
El Roz A, Bard JM, Valin S, Huvelin JM, Nazih H. Macrophage apolipoprotein E and proliferation of MCF‐7 breast cancer cells: role of LXR. Anticancer Res. 2013;33:3783–9.
Pencheva N, Buss CG, Posada J, Merghoub T, Tavazoie SF. Broad‐spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation. Cell. 2014;156:986–1001.
Noghero A, Perino A, Seano G, Saglio E, Lo Sasso G, Veglio F, et al. Liver X receptor activation reduces angiogenesis by impairing lipid raft localization and signaling of vascular endothelial growth factor receptor‐2. Arterioscler Thromb Vasc Biol. 2012;32:2280–8.
Katiyar S, Liu E, Knutzen CA, Lang ES, Lombardo CR, Sankar S, et al. REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A‐DDB1 ubiquitin ligase. EMBO Rep. 2009;10:866–72.